Pathophysiological Ramifications of Diabetic Condition: A Review

Shahi, A Talebi Mazraeh; Vss, Prasad; Imam, Syed Sarim; Muheem, Abdul; Jahangir, Mohammed Asadullah

doi:10.4066/2249-622x.65.18-845

Cited by 6 publications

(5 citation statements)

References 69 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Obesity is a serious concern which directly of indirectly influences pathophysiology of many other diseases especially endocrine disorders [7][8][9][10][11][12][13]. Hence, the based on the protocol the following points will be discussed.…”

Section: Discussionmentioning

confidence: 99%

Evaluation of the Efficacy of Pippalyadi Basti and Lekhan Basti in the Management of Medoroga with Special Reference to Obesity – A Protocol

Wairagade¹

2022

J Pharm Res Sci Technol

View full text Add to dashboard Cite

Background: The conventional concept of etiopathogenesis, prognosis, and management of obesity is very similar and equally advanced to the Medoroga/Sthaulyaroga of Ayurveda, which was conceived in 1500 BC by Acharya Charaka. Overweight or obesity is mostly found in people with predominantly Kapha-type constitutions. According to Acharya Charak, apart from the genetic factors, diet (like shleshmakar, abhishayandi) & lifestyle (like avyayam, divaswapna) are the main contributing factors in the aetiopathogenesis of Medoroga. As per previous study Lekhana Basti was found to have moderate results in obesity. Pippalyadi has Chitraka and Pippali in addition to the other components of Lekahan basti so could have better results in correcting the vitiated Agni. Therefore, Pippalyadi basti is chosen for the current study. Objectives: • To evaluate efficacy of Pippalyadi Basti in the management of Medoroga. • To compare the efficacy with Lekhana Basti • Conceptual study of Medoroga in Ayurvedic texts and Obesity in modern medicine. • Effect of Pippalyadi Basti & Lekhan Basti on B.M.I. Methodology: D.Y. Patil Ayurved Hospital, Samhitas & modern books of medicine, Pharmacy attached to college for the preparations of the drugs, international & national medical journals and magazines, OPD, IPD , Labs , other provisions of the hospitals will be availed to do this intended work. Expected Results: Changes will be observed in objective outcomes. Conclusion: Conclusion will be drawn by suitably analyzing data.

show abstract

Section: Discussionmentioning

confidence: 99%

Evaluation of the Efficacy of Pippalyadi Basti and Lekhan Basti in the Management of Medoroga with Special Reference to Obesity – A Protocol

Wairagade¹

2022

J Pharm Res Sci Technol

View full text Add to dashboard Cite

show abstract

“…Vedolizumab received approval from the European Medicines Agency (EMA) and US FDA in 2014 for the treatment of moderate to severe UC and CD. Guidelines currently recommend vedolizumab in both diseases as a first-line biologic agent or for patients who are refractory to a TNF antagonist [66][67][68][69][70][71][72][73][74].…”

Section: Discussionmentioning

confidence: 99%

Vedolizumab in Ulcerative Colitis and Crohn’s Disease-A Systematic Review

P¹

2021

Int Pharm Sci

View full text Add to dashboard Cite

Background: Vedolizumab is a fully humanized monoclonal IgG-1 antibody that selectively inhibits the interaction between α4β7 integrin and mucosal addressin cell adhesion molecule-1 (MAdCAM-1). It prevents lymphocyte translocation from the blood into the inflamed gut tissue, resulting in a reduction in local inflammation. Ulcerative colitis (UC) and Crohn’s disease (CD) are inflammatory conditions of the bowel affecting approximately 1.4 million people in the US. The efficacy of the drug was studied. Methods: The outcome measures for Phase 3 and randomized clinical trials in ulcerative colitis and Crohn’s disease, was as per GEMINI 1, 2, and 3 for its efficacy. Results: A total of 309 out of 499 reported vedolizumab AEs. In comparison with all other drugs, 3PRR signals were detected including joint-related symptoms like arthralgia, upper respiratory tract infections like nasopharyngitis and sinusitis, and upper respiratory tract symptoms like oropharyngeal pain. Among the vedolizumab-associated reports with serious outcomes, the drug was used for CD in 52.5% and UC in 27.4% compared with 86.1% and 13.9% for the anti-TNFs-associated reports. Although safety data from both these studies suggest VDZ is safe, larger studies with longer follow-up will be necessary to determine the potential risk for the development of PML. Conclusion: There is limited information on other potential confounders, such as co-morbidities, duration, and severity of disease, disease phenotype, surgical history, smoking, and concurrent IBD treatment. The benefit and risk profile of combining Vedolizumab with anti-TNF-α agents in the treatment of IBD will need to be examined. Vedolizumab is revolutionary in the community of inflammatory bowel disease, especially with the potential advantage for VDZ’s selectivity to the gastrointestinal immune system. Vedolizumab provides an alternate class to biologic therapy with an encouraging response and safety profile.

show abstract

“…Many factors affect normal level of thyroid hormones which leads to complications in thyroid functions. It arises due to excessive thyroid hormones productions or not enough (Shahi et al, 2018).…”

Section: Introductionmentioning

confidence: 99%

Pharmacological evaluation of clove oil emulsion on propylthiouracil induced hypothyroidism in wistar rats

Lanjekar¹,

Kolhe²,

Tembhurne³

2020

Asian J Pharm Pharmacol

View full text Add to dashboard Cite

Objective: Material The present work was carried out to evaluate the effect of clove oil for enhancing thyroid function. and methods: Wistar rats received propylthiouracil at a dose 0.3mg/kg/bw (orally) daily for 21 days as pretreatment for induction of hypothyroidism and after induction treated with clove oil emulsion at dose 100, 200 and 300 mg/kg (orally) daily for 21 days. All animals were observed throughout the whole experiments and note down body weight of each animal once in week. Blood samples were taken before and after treatment and hormonal level assay was performed. Histopathological analysis was also assessed Significantly increase value of T3, T4 and. Results and conclusion: compared with control, standard and test value. Histopathological changes were observed with few vacuolation. It was concluded that clove oil emulsion plays vital role on propylthiouracil (PTU) induced hypothyroidism by enhancing thyroid functions in experimental wistar rats.

show abstract

Pathophysiological Ramifications of Diabetic Condition: A Review

Cited by 6 publications

References 69 publications

Evaluation of the Efficacy of Pippalyadi Basti and Lekhan Basti in the Management of Medoroga with Special Reference to Obesity – A Protocol

Evaluation of the Efficacy of Pippalyadi Basti and Lekhan Basti in the Management of Medoroga with Special Reference to Obesity – A Protocol

Vedolizumab in Ulcerative Colitis and Crohn’s Disease-A Systematic Review

Pharmacological evaluation of clove oil emulsion on propylthiouracil induced hypothyroidism in wistar rats

Contact Info

Product

Resources

About